In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 111 to 120 of 373

TitleTypeExpected publication date
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]Technology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]Technology appraisal guidance
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)NICE guidelineTBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409Technology appraisal guidanceTBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidanceTBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All